APOLIPOPROTEIN A-I, HUMAN Chemical Properties

storage temp. 

−20°C

solubility 

H₂O: 1 mg/mL, clear, colorless

form 

solution (clear)

color 

colorless

biological source

human

Safety Information

Hazard Codes 

B

Safety Statements 

23-24/25

WGK Germany 

3

F 

10-21

MSDS

• Language:English Provider:SigmaAldrich

APOLIPOPROTEIN A-I, HUMAN Usage And Synthesis

Uses

Apolipoprotein A-I human has been used in the cholesterol efflux assay.

General Description

ApoA-I, which is found exclusively in HDL, has a unique ability to capture and solubilize free cholesterol. This apoA-I ability enables HDL to remove excess peripheral cholesterol and return it to the liver for recycling and excretion. This process, called reverse cholesterol transport, is though to inhibit atherogenesis. For this reason HDL is also known as the "good cholesterol." The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I (called apoA-I Milano). The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic vascular diseases.

Biochem/physiol Actions

ApoA-I (apolipoprotein A-I), which is found exclusively in HDL (high-density lipoprotein), has a unique ability to capture and solubilize free cholesterol. This apoA-I ability enables HDL to remove excess peripheral cholesterol and return it to the liver for recycling and excretion. This process, called reverse cholesterol transport, is thought to inhibit atherogenesis. For this reason HDL is also known as the "good cholesterol." The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I (called apoA-I Milano). The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic vascular diseases. Changes in the level of serum apoA-I may serve as a prognostic marker for non-metastatic nasopharyngeal carcinoma. Low levels of apoA-I in the plasma is linked to hyperhomocysteinemia.

Description

Apolipoprotein A-I Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 243 amino acids and having a molecular mass of 28.1kDa.
The APOA1 is purified by proprietary chromatographic techniques.

Source

Escherichia Coli

Background

APOA1 (Apolipoprotein A-1) is a human protein with a specific role in lipid metabolism being the main protein component of HDL in the plasma. APOA1 promotes cholesterol efflux from tissues to the liver for excretion. Furthermore, APOA1 is a cofactor for LCAT, which is responsible for the formation of most plasma cholesteryl esters. In addition, APOA1 activates spermatozoa motility as part of the SPAP complex. The APOA1 gene is strongly linked with two other apolipoprotein genes on chromosome 11. Defects in the APOA1 gene are linked to HDL deficiency including Tangier disease, and with systemic non-neuropathic amyloidosis. High levels of APOA1 are linked to the manifestation of asthma and atopy.

APOLIPOPROTEIN A-I, HUMAN(1426185-50-3)Related Product Information

• CD40 Ligand
• TRBC2
• BTN3A3
• Recombinant Human CD30/TNFRSF8/CD30L Receptor (C-Fc)
• Cathepsin E
• HUMAN EOTAXIN-2
• Pre-Fusion glycoprotein F0
• Fc epsilon RI alpha
• CD300A
• col1a1a